Introduction
immersed 2 cm below the dissolution medium at t = 0. Samples of the dissolution medium were taken at t = 0; 2. 5; 5; 7.5; 10; 15; 20; 25; 30 Differences in means of Fu, TO and Td of the formulations were analysed for statistical significance by Student's t-test for unpaired data. P values < 0.05 were considered as statistically significant.
In vivo study Study population
The study was conducted at the hospital 'Medisch Spectrum Twente' in Enschede, the Netherlands.
Ten healthy, male volunteers between 21 and 52 years participated in the study on a informed consent base. Excluded were subjects with known intolerance to benzodiazepines.
The study was approved by the local Institutional Review Board.
Study design
A cross-over design was used in the study in order to minimize interindividual differences. The suppository, micro-enema and liquid-filled capsule were self-administered rectally by each volunteer in randomized order. Oral administration of the liquid-filled capsule took place after overnight fasting, after which volunteers continued fasting for another 3 hours.
A wash-out period of one week was maintained between the administration of the different formulations. During the first hour after rectal administration the volunteers stayed in lying position, in order to minimize variability in rectal absorption.
After completion of the study, volunteers were asked for their preference in rectal formulations, with regard to handling and comfort.
Dosage forms
Based on the data of the in vitro study (see Results), temazepam suppositories (2.3 ml) were prepared in a polyethylene glycol 1540 base. The micro-enema contained temazepam in a 2 ml solution of glycofurol:ethanol 96%:water (5:1:4), similar to the composition of diazepam micro-enemas [3] . Methylhydroxybenzoate (0.15%) was added as a preservant. The liquid-filled capsule (Normison@) was used both orally and rectally.
All preparations contained 10 mg of temazepam. were run with each batch of samples. Using the standard curves, serum concentrations were calculated with Turbochrom III (Perkin-Elmer) software system. The assay was validated for the serum level-range between 10 pg/l and 400 pg/l for oxazepam and temazepam [8] .
Recovery of oxazepam and temazepam was 92.4% and 96.7% respectively. The lower assay limit was 10 pg/l, the limit of detection was 2 pg/l for both oxazepam and temazepam. The standard deviation (y) of the assay, in relation to the serum level (x), was described by the following polynome y = 2.01 + 5.27*10m3x + 7.27*1O-5x2 -6.38*10w8x3 (n=6) for temazepam and y= -0.09 + 9.99'1 Om2x -5.71 *l Os4x2 + 1.07*1 Oe6x3 (n=6) for oxazepam. The relative bioavailability (F,,) was calculated by dividing the AUC of the rectal formulation by the AUC after oral intake of the liquid-filled capsule. The cumulative input of the different rectal formulations was calculated by numerical deconvolution, using the software program KINBES. The mean differences of the interindividual parameters using rectal formulations were tested for statistical significant differences with the results after oral administration, using the Student's t-test for paired data (P < 0.05).
Results
In vitro study The release profiles are shown in Figure 1 . Release parameters, calculated by WEIFIT, are summarized in Table 1 . Despite complete melting of the suppositories within 10 minutes, release of temazepam from the fatty base was incomplete and inconsistent and release parameters could not be calculated by curvefitting. The suppositories with polyethylene glycol bases showed a reproducible and complete release of temazepam within 30 minutes. No significant differences in Fu were found between the two polyethylene glycol bases. However, Td of the polyethylene glycol 1540 base was significantly lower than Td of the polyethylene glycol 1540:4000 base, indicating a faster release of temazepam from polyethylene glycol 1540. The liquid-filled capsules showed an inconsistent release with a high variation in lag-time and Td between the capsules tested. However, within 20 minutes the release process was completed.
In vivo study All volunteers completed the study. No side-effects were experienced, except for a slight drowsiness in some volunteers.
The serum concentration-time profiles and the cumulative input of the different rectal formulations and the oral formulation are shown in Figure Za Table 2 .
The AUC of both micro-enema and suppository did not differ significantly from the AUC of the oral capsule, indicating an equivalent bioavailability. However, the AUC after rectal administration of the capsule, was significant lower (P~0.05) than the AUC after oral administration.
After administration of the micro-enema absorption started almost immediately. In comparison to the micro-enema and the oral capule, the suppository showed a slower absorption process (ka 1.5 f 1.3 hour-') and a significant higher t,,, (1.5 f 0.4 hour).
The liquid-filled capsule showed an highly erratic absorption-profile after rectal administration. Only minor absorption occurred in five of the ten volunteers, with hardly any absorption in two volunteers. The other volunteers showed absorption-profiles comparable with oral intake. Serum-concentrations of oxazepam were below quantification levels in all samples. The observed pharmacokinetic parameters after oral administration of the liquid-filled capsule: Cl 81 f 25 ml/kg/hour and tl/z el. 9.3 -I-5.4 hour ( Table 2 , Cl corrected for body-weight of the volunteers) were similar to data reported in literature (Cl 60-120 ml/kg/hour, t1/2 el. 6-11 hour) [9] . Serum-concentration vs. time profiles and cumulative input Serum-concentration vs. time profiles and cumulative input (expressed in relative units, compared to oral input) after rectal (expressed in relative units, compared to oral input) after rectal administration of 7 0 mg temazepam in a PEG suppository administration of 10 mg temazepam in a (n=70).
glycofural/ethanol/water enema (n= 7 0). Cl and tl/z el. of the rectal formulations did not differ significantly from Cl and tl/z el. after oral administration, justifying the use of oral data as referencedata.
With respect to handling of the drugs, the selfadministration of the capsule was experienced as most difficult (r-1=9) because of 'sliding problems' and the suppository as most easy (r-1=9). With regard to comfort, 5 volunteers reported no discomfort with any of the rectal formulations.
Minor local irritation was experienced with the suppositories (r-1=3), the enema (n=l) and the capsule (n=l).
Discussion
In vitro study The release data from the polyethylene glycol bases correspond with the expected optimal release of hydrophobic compounds like temazepam from a water-soluble base like PEG [3] . Comparing the PEG bases studied, the fastest release of temazepam is obtained with the PEG 1540 base, as quantified by the lowest Td. These findings correlate with a higher melting point of a suppository base composed of a mixture of PEG 1540 and PEG 4000 compared to purely PEG 1540. Release of temazepam from a fatty base was slow, probably due to adherence of the hydrophobic compound to the base and wetting problems. Similar results have been found for the release of diazepam from a fatty base [IO] . An almost instantenous release of temazepam from the liquidfilled capsules was shown due to 'bursting' of the capsule, but the period to release varied from 5 to 15 minutes after immersing the capsule. An explanation for these differences is difficult to give, however slight sticking of the capsule to the immersing device may have influenced the release process. Therefore, the results of the capsule were not included in the statistical analysis.
In vivo study For patients who cannot take a hypnotic orally, a rectal formulation can be an easy and safe alternative to parenteral administration of a benzodiazepine. In the literature
[3], rectal administration of benzodiazepines for purposes other than hypnotic use, has shown to be effective: a diazepam enema and a midazolam enema were effective as anti-epileptic and pre-medication respectively. A optimal rectal formulation of a drug for hypnotic purposes should have the following characteristics: non-irritant, easy to prepare and to (self)-administer, no lag-time, a short t,,, and an bioavailability equivalent to oral use.
The hypnotic temazepam has the advantages of an intermediate tl/z el. (6-l 1 hour), no active metabolites (in clinically relevant concentrations) and a worldwide experience of many years. Considering the need for a rectal hypnotic, development of a suitable rectal formulation of temazepam could mean a significant improvement in clinical practice.
In this study, none of the patients fell asleep after using either rectal or oral formulation of 10 mg temazepam.
These findings are consistent with other day-time studies with hypnotics. Since no objective hypnotic effects were studied, no conclusions can be drawn on hypnotic effects of either formulation, other than interpretating the pharmacokinetic data. Looking only at the C,,, of temazepam, obtained with the rectal formulations, none of the formulations appears to be in the therapeutic range described in literature (300-800 pug/l) [I I]. However, a clear relation between serum levels and hypnotic effect has never been established for temazepam.
An effective rectal dosage of temazepam should probably be higher than 10 mg (f.i. 20 mg), but this has to be confirmed in pharmacodynamic studies. Considering the results found in this study, the micro-enema appears to be the optimal rectal formulation for temazepam with a short t,,, and a F,,, equivalent to I. Taking into account the ease of self-administration and the ease of pharmaceutical (bulk-)preparation, the PEG-suppository appears to be a possible alternative formulation, if accepting its longer t,,, and thus a slower therapeutic effect.
Temazepam from rectally administered liquid-filled capsules was overall unpredictably and inconsistently absorbed, despite good results in some individuals. Since oral absorption was fast and reproducible, it is therefore likely that the small volume of fluid in the rectum may be the limiting step in the absorption process of rectally administered capsules. Also, the intraluminal pressure may have a small influence on the release profiles of rectally administered drugs. Apparently, these factors were highly variabel within the tested population, resulting in an variable lagtime and bioavailability of temazepam in rectally administered liquid-filled capsules. Apart from the pharmacokinetic aspects, the difficulties in (self-) administration makes the liquid-filled capsule unsuitable for rectal use. The current practice of rectal administration of temazepam in a liquid-filled capsule should therefore be discouraged.
Conclusion
Based on pharmacokinetic data, rectal administration of temazepam can be effective, dependent on the formulation used.
Both the micro-enema, containing temazepam in a solution of ethanol, glycofurol and water, and the suppository with a polyethylene glycol base, can be used as rectal formulations of temazepam. Further pharmacodymanic studies are needed for determination of the proper dosage. The commercially available, liquid-filled capsule is less suitable for rectal administration.
